Influential Goldman analyst, Jami Rubin, says Teva should sell off some of its parts now that it is faced with its biggest drug, Copaxone, going generic. This is not new for Rubin. She has previously advised Pfizer's Ian Read, and J&J's Alex Gorsky to do the same. When Gorsky demurred, she recommended shareholders sell their holdings. She has also supported Merck and Novartis in their strategic reviews to split up their holdings.
Teva's stock has languished for the better part of the last two years and its current desire to cut $1 B out of R&D spending will go only so far say analysts. Rubin advocates for more. Call it the "anti-string of pearls" strategy as Teva undoes what it previously put together under Levin and others following its acquisition strategy for growth. Amazing how fast strategy can fall out of vogue, eh? See Fierce Biotech.
Posted by Bruce Lehr Feb 10th 2014.